Parabilis Medicines Inc.
PBLS | NASDAQ
$28.32
-$0.38 (-1.32%)
At close: Oct 30, 2026, 4:00 PM ET
$28.16
-$0.16 (-0.56%)
Pre-market:
Nov 2, 2026, 9:16 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 |
|---|---|---|
Net Income | -145.89M | -117.91M |
Depreciation & Amortization | 2.5M | 2.11M |
Stock-Based Compensation | 3.32M | 4.31M |
Other Working Capital | -4.83M | -8.48M |
Other Non-Cash Items | 7.24M | 6.98M |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | 9.12M | 910K |
Operating Cash Flow | -123.71M | -103.61M |
Capital Expenditures | -306K | -879K |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -16.66M | -90.86M |
Sales Maturities Of Investments | 56.73M | 121.98M |
Other Investing Acitivies | n/a | n/a |
Investing Cash Flow | 39.76M | 30.24M |
Debt Repayment | -3.08M | n/a |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | n/a | n/a |
Financial Cash Flow | 64.38M | 78.09M |
Net Cash Flow | -19.57M | 4.7M |
Free Cash Flow | -124.02M | -104.49M |
Adj. Free Cash Flow | -127.34M | -108.8M |
Maintenance CapEx | -306K | -879K |
Growth CapEx | n/a | n/a |
Owner Earnings | -124.02M | -104.49M |
Add to Watchlist
Select watchlists to add or remove PBLS